[
  {
    "name": "Olaparib + Sapacitabine in BRCA Mutant Breast Cancer",
    "country": "FR",
    "start_date": "2019-01-01",
    "end_date": "2025-08-01",
    "sponsor": "Sanofi",
    "canceled": false,
    "study_type": "interventional",
    "primary_purpose": "treatment"
  },
  {
    "name": "Topical Calcipotriene Treatment for Breast Cancer Immunoprevention",
    "country": "fr",
    "start_date": "2018-03-20",
    "end_date": "2032-09-10",
    "sponsor": "Sanofi",
    "canceled": false,
    "study_type": "interventional",
    "primary_purpose": "treatment"
  },
  {
    "name": "Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer",
    "country": "ES",
    "start_date": "2018-06-13",
    "end_date": "2025-07-17",
    "sponsor": "Sanofi",
    "canceled": true,
    "study_type": "interventional",
    "primary_purpose": "treatment"
  },
  {
    "name": "Supine MRI in Breast Cancer Patients Receiving Neoadjuvant Therapy",
    "country": "IT",
    "start_date": "2022-06-15",
    "end_date": "2030-12-24",
    "sponsor": "AstraZeneca",
    "canceled": false,
    "study_type": "interventional",
    "primary_purpose": "treatment"
  },
  {
    "name": "Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer",
    "country": "DE",
    "start_date": "2016-03-08",
    "end_date": "2026-10-10",
    "sponsor": "AstraZeneca",
    "canceled": false,
    "study_type": "interventional",
    "primary_purpose": "treatment"
  },
  {
    "name": "Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis",
    "country": "AT",
    "start_date": "2019-02-26",
    "end_date": "2025-05-05",
    "sponsor": "AstraZeneca",
    "canceled": true,
    "study_type": "interventional",
    "primary_purpose": "treatment"
  }
]
